Clinical Trial Update: Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia [Phase 2]

View source ↗

Summary

A Phase 2 randomized, double-blind, placebo-controlled trial evaluating LB-102 for acute schizophrenia has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• LB-102 (LB-102)

Snippet

Sponsor: LB Pharmaceuticals Inc. | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2025-10-22